← Back to headlines
Johnson & Johnson Halts Development of Multiple CAR-T Lymphoma Programs
Johnson & Johnson has announced the discontinuation of several CAR-T cell therapy programs aimed at treating large B-cell lymphoma, impacting its oncology pipeline.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
